Drugs / FM101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03879928 | Jan → Aug 2019 | — | Future Medicine | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04585100 | Oct 2020 → Jan 2023 | ocular hypertension | Future Medicine | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04710524 | Jun 2021 → May 2023 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Future Medicine | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FM101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04585100 ↗ |
| Route | Oral | “The study drug (FM101 and placebo comparator) will be administered orally as SAD doses” NCT03879928 ↗ |